For the quarter ending 2026-03-31, SLNO made $94,603K in revenue. $29,125K in net income. Net profit margin of 30.79%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenue, net | 94,603 | 42,393* | 66,018 | 32,657 |
| Cost of goods sold | 1,198 | -55* | 1,141 | 696 |
| Research and development | 11,274 | 14,299* | 8,405 | 9,147 |
| Selling, general and administrative | 50,369 | 39,141* | 33,753 | 28,238 |
| Change in fair value of contingent consideration | 484 | 2,964* | 614 | 1,101 |
| Total operating expenses | 63,325 | 56,348* | 43,913 | 39,182 |
| Operating income (gain) | 31,278 | -13,955* | 22,105 | -6,525 |
| Interest income, net | 4,927 | 4,216* | 5,298 | 3,193 |
| Interest expense | 1,292 | 1,327* | 1,390 | 1,376 |
| Total other income (expense), net | 3,635 | 2,889* | 3,908 | 1,817 |
| Income (loss) before provision for income taxes | 34,913 | - | - | - |
| Provision for income taxes | 3,535 | - | - | - |
| Net income (gain) | 31,378 | -11,067* | 26,013 | -4,708 |
| Net unrealized loss (gain) on marketable securities | -2,225 | -125* | 261 | -153 |
| Foreign currency translation adjustment | -28 | -22* | 14 | 12 |
| Total comprehensive income (gain) | 29,125 | -11,214 | 26,288 | -4,849 |
| Basic EPS | 0.6 | -0.231 | 0.49 | -0.09 |
| Diluted EPS | 0.59 | -0.217 | 0.47 | -0.09 |
| Basic Average Shares | 52,091,047 | 48,641,383 | 53,328,094 | 50,483,281 |
| Diluted Average Shares | 53,066,971 | 51,749,461 | 54,921,916 | 50,483,281 |
SOLENO THERAPEUTICS INC (SLNO)
SOLENO THERAPEUTICS INC (SLNO)